[ad_1]
Pfizer announced to Romania that there are problems at the Belgium factory and that the vaccine doses will arrive 24 hours late, announced Dr. Valeriu Gheorghiţă, on Antena 3, on Sunday night.
“Pfizer informed me that due to organizational and software problems at the Belgian factory, the vaccines will be delivered one day late. It starts on December 29 and December 30, respectively. (…) There is this delay in eight European countries. Some of the countries received today (Sunday – no.), Another part will receive tomorrow and the day after tomorrow. In addition, in Romania (…) on the 29th the trenches will arrive for Bucharest, for Timişoara and Cluj in Romania, and On December 30, the trenches assigned to Iaşi, Braşov, Constanţa and Craiova will arrive, ”said the coordinating doctor.
Gheorghiţă also said that there is no delivery schedule, but only the certainty that the doses of the vaccine will reach our country.
“There will be a tranche of about 150,000 doses per week. I want to make one more point: the delivery time is estimated. It is true that it will be weekly, but the exact day on which it is delivered may change. Pfizer agrees to notify us at least two days before the delivery time, precisely in order to organize the logistical process of reception and storage ”, said the coordinator of the National Coordinating Committee for Vaccination Activities against COVID -19.
GCS announced that delivery was delayed in eight countries due to technical problems with the manufacturer.
Thus, the new anti-COVID-19 vaccines will arrive on Tuesday in Bucharest, Cluj and Timisoara, and on December 30 in Brasov, Constanta, Craiova and Iasi.
Romania should have received 144,000 doses of vaccine on Monday, for more than 370 regional vaccination centers in the country.
For the most important news of the day, broadcast in real time and presented equally, like our Facebook page!
Follow Mediafax on Instagram to see amazing images and stories from around the world!
The content of the website www.mediafax.ro is intended exclusively for your information and personal use. Is prohibited republish the content of this site in the absence of an agreement from MEDIAFAX. To obtain this agreement, contact us at [email protected].
[ad_2]
